Delving into the Latest Updates on Interferon alpha-2b(Hanmi Pharmaceutical Co., Ltd.) with Synapse

Overview

Basic Info

Drug Type

Interferons

Synonyms

Interferon alpha-2b (Hanmi Pharma), LAPS-IFNa

+ [2]

Target

IFNAR

Action

agonists

Mechanism

IFNAR agonists(Interferon alpha/beta receptor agonists)

Therapeutic Areas

NeoplasmsInfectious DiseasesDigestive System Disorders

Active Indication-

Inactive Indication

Chronic hepatitis C genotype 1Neoplasms

Originator Organization

Hanmi Pharmaceutical Co., Ltd.

Active Organization-

Inactive Organization

Hanmi Pharmaceutical Co., Ltd.

License Organization-

Drug Highest PhaseDiscontinuedPhase 2

First Approval Date-

Regulation-

Login to view timeline

Purpose To report an unusual case of ocular surface squamous neoplasia (OSSN) associated with human papilloma virus (HPV)-16 infection with an atypical morphology in a young otherwise healthy patient. Case description A 17 year-old healthy male was referred to our department for evaluation of a corneal infiltrate with anterior stromal neovascularization in the right eye. One year before, the patient underwent an excision of a corneo-conjunctival lesion that was located inferiorly in the same eye. Histopathological analysis had shown moderate and severe dysplasia of the conjunctival epithelium and resulted positive for HPV-16. We performed a diagnostic incisional biopsy of the limbal conjunctiva and of the corneal epithelium for histological examination and molecular testing for HPV and Chlamydia by using polymerase chain reaction (PCR). Histopathologic evaluation demonstrated low-grade dysplasia of conjunctiva. PCR testing of the corneal epithelium was positive for HPV-16, similarly to the first biopsy performed by another centre. The patient was successfully treated with topical interferon alfa-2b (1,000,000 IU/ml) for a total of six months. After the treatment, the corneal infiltrate improved dramatically with regression of neovascularization and improvement of corneal transparency and vision. Discussion The present report described an atypical presentation of HPV-related OSSN due to its unusual morphology, young age of onset and absence of associated comorbidity. Conclusion Conservative treatment with topical interferon-alpha 2b could be used to treat successfully HPV-16 positive OSSN, with no corneal irregularity or potential loss of vision compared to surgical excision.

01 Sep 2024·Brazilian Journal of Otorhinolaryngology

Interferon alpha-2b treatment for exophytic nasal papillomas and human papillomavirus infection

Article

Author: Andrey, Boyko ; Anastasia, Kozlova ; Pavel, Tregub ; Vladimir, Petrovskii ; Irada, Ibrahimli ; Inga, Popova ; Timur, Shadyev ; Irina, Apollonova ; Svetlana, Starostina ; Tatiana, Degtyarevskaya

OBJECTIVESExophytic Sinonasal Papilloma (ESP) is a benign tumor of the sinonasal tract. Complete surgical excision by endoscopic surgery is the treatment of choice. However, a high recurrence rate (36% at 5-year follow-up) is associated with this method, which may indicate the presence of microorganisms such as Human Papillomavirus (HPV). It is important to note that the standard treatment for ESP does not include antiviral drugs. In our study, we are testing the effectiveness of an interferon-containing drug in reducing recurrence and postoperative reactions in patients with ESP.METHODSWe included 78 patients aged 23-83 years with a confirmed diagnosis of ESP by rhinoscopy and nasal endoscopy and a positive PCR test for HPV in nasal scrapings. To compare the results, we divided the patients into main and control groups. The main group received recombinant human interferon after surgery, while the control group did not receive the drug. We performed a statistical analysis to compare the proportion of patients without reactive manifestations at different stages of the postoperative period, as well as to compare the proportion of patients with recurrent ESP at certain stages of observation.RESULTSThe introduction of recombinant human interferon accelerated the resolution of postoperative reactions and promoted the healing of the nasal mucosa after surgical removal of the ESP. We also found a statistically significant association between treatment with recombinant interferon and a reduction in the recurrence rate of ESP.CONCLUSIONAccording to the results of the study, it was found that in the main group of patients who received rhIFN-α2b (recombinant human Interferon alpha 2b) in the postoperative period, the frequency of relapses of ESP and the time of postoperative recovery were significantly lower than in patients in the control group who did not take the drug.LEVEL OF EVIDENCECohort Study.

01 Jan 2024·Therapeutic Advances in Medical Oncology

Short-term outcomes of combined therapy with sirolimus and interferon-alpha 2b for advanced hepatic epithelioid hemangioendothelioma

Article

Author: Tan, Haidong ; Liu, Liguo ; Yang, Shiwei ; Zhou, Ruiquan ; Si, Shuang ; Liu, Xiaolei ; Han, Dongdong

Background: Hepatic epithelioid hemangioendothelioma (EHE) is an extremely rare tumor, and no standard therapy has been established yet. Objectives: The aim of this study was to investigate the short-term results of combined therapy with sirolimus and interferon-alpha 2b (IFN-a 2b) (SI therapy). Methods: From January 2022 to April 2023, 40 patients histologically diagnosed with hepatic EHE and progressive disease received SI therapy. All patients were regularly evaluated for the safety and efficacy of the SI therapy. Patients who received SI therapy for <3 months without a tumor status evaluation after treatment were excluded. Results: Twenty-nine patients with hepatic EHE were included in this study. The Eastern Cooperative Oncology Group (ECOG) performance status was 0 in 19 (65.5%) patients and 1 in 10 (34.5%) patients. The median duration of the SI therapy was 8 months (range, 3–15 months). Twenty-three (79.3%) patients showed a decrease in tumor size, including 11 (37.9%) patients who achieved a partial response and one (3.4%) who achieved a complete response; the objective response rate was 41.4%. Stable disease was observed in 13 (44.8%) patients, with a disease control rate of 86.2%. Adverse events (AES) were observed in 18 patients, including leukopenia (31.0%), oral ulcers (13.8%), and liver injury (10.3%). No severe (grade ⩾ 3) AEs were recorded, and SI therapy was not interrupted for any patient due to AEs. Conclusion: Sirolimus and IFN-a 2b may have synergistic effects in the treatment of hepatic EHE. SI therapy is a safe and effective treatment for hepatic EHE patients with good ECOG performance status.

100 Deals associated with Interferon alpha-2b(Hanmi Pharmaceutical Co., Ltd.)

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	Interferon alpha-2b(Hanmi Pharmaceutical Co., Ltd.)	L03AB05	-

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Chronic hepatitis C genotype 1	Phase 2	Mexico	Hanmi Pharmaceutical Co., Ltd.	01 Jul 2013
Neoplasms	Phase 2	Netherlands	Hanmi Pharmaceutical Co., Ltd.	-

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


S-0008 (ASCO2012)	Phase 3	Melanoma Adjuvant	432	High-dose interferon alpha-2b	(fsohkydbsv) = eixmtzzgsv ebgkyivjtu (uyomufpdcz, 4.5–9.3) View more	Positive	20 May 2012
S-0008 (ASCO2012)	Phase 3	Melanoma Adjuvant	432	Cisplatin, vinblastine, DTIC plus IL-2 and interferon	(fsohkydbsv) = mgjpkkwevn ebgkyivjtu (uyomufpdcz ) View more	Positive	20 May 2012
ASCO2008	Phase 2	Metastatic Renal Cell Carcinoma Second line	49	Capecitabine + Interferon alpha-2b	(drhrymofjn) = sxyyrcohli pfpfcmnyst (tshxjjestp, 4.7 - 11.4)	Positive	20 May 2008
ASCO2005	Not Applicable	Melanoma Adjuvant	-	High-dose interferon alpha 2b (HD-IFN)	(nvboipbnon) = ngsnqvznij jzdncrameu (ebvvsttgwq, 34.9–90.7) View more	-	01 Jun 2005
SWOG 0026 (ASCO2004)	Phase 2	Melanoma	26	Interferon alpha-2b and thalidomide	(ammeltbhln) = cozmzjndsj vpxrcgqlbc (wmpbcbbryu, 40 - 79) View more	Negative	15 Jul 2004
IAS2001	Not Applicable	HIV Infections \| Hepatitis C, Chronic	110	Ribavirin/Interferon α-2b combination therapy	(lbshgmxdlo) = loxrygubfq zjqytlvblx (upurtbrucj )	-	01 Jan 2001
IAS2001	Not Applicable	HIV Infections \| Hepatitis C, Chronic	110	Interferon α-2b alone	(lbshgmxdlo) = qsrveulrsx zjqytlvblx (upurtbrucj )	-	01 Jan 2001

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data